Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics. Issue 8 (August 2022)

• Record Type: Journal Article
• Authors: Khan, Abrar A.; Gupta, Vinayak; Mahapatra, Nitish R.
• Is Part Of: Drug discovery today. Volume 27:Issue 8(2022)
• Page Start: 2170
• Page End: 2180
• Publication Date: 2022-08
• Subjects: Cholesterol -- Cardiovascular -- Lipid metabolism -- miRNA -- Cardiometabolic therapeutics; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2022.05.003
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: Dysregulation of lipid metabolism is associated with cardiometabolic diseases. microRNAs have emerged as crucial regulators of lipid metabolism. We highlight key regulatory microRNAs in lipid homeostasis. Several microRNAs emerge as attractive candidates for cardiometabolic therapeutics. Abstract: Dysregulation of lipid metabolism is associated with cardiovascular/metabolic diseases, including atherosclerosis, liver diseases and type 2 diabetes mellitus (T2DM). Several miRNAs have been reported as regulators of different stages of lipid homeostasis, including cholesterol/fatty acid biosynthesis, degradation, transport, storage, and low-density (LDL) and high-density lipoprotein (HDL) formation. Indeed, various miRNAs are emerging as attractive therapeutic candidates for metabolic/cardiovascular disease (CVD). Here, we summarize the roles of miR-19b, miR-20a, miR-21, miR-27, miR-29, miR-34a, miR-144, miR-148a, and miR-199a in post-transcriptional regulation of genes involved in lipid homeostasis and their therapeutic potential. We also discuss experimental strategies for further development of these miRNAs as novel cardiometabolic therapeutics.